In the Original Investigation titled “Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors,”1 published February 24, 2022, an Additional Information section was added to indicate that the study was endorsed by the Italian Association for Neuroendocrine Tumors (It.a.net). This article has been corrected.1
Reference
- 1.Pusceddu S, Prinzi N, Tafuto S, et al. Association of upfront peptide receptor radionuclide therapy with progression-free survival among patients with enteropancreatic neuroendocrine tumors. JAMA Netw Open. 2022;5(2):e220290. doi: 10.1001/jamanetworkopen.2022.0290 [DOI] [PMC free article] [PubMed] [Google Scholar]